Shaanxi Micot Pharmaceutical Technology reported that injectable TrkB agonist MT-200605 met Phase 2 endpoints in acute ischemic stroke. The program targets the BDNF/TrkB pathway, aiming to interrupt post-stroke ischemic cascade and support neurological repair. Micot said MT-200605 is designed to cross the blood-brain barrier and includes a mechanism intended to mitigate oxygen free radicals. The company characterized the study as part of its neuroprotective development pipeline. Phase 2 success can influence next-step trial design and timelines for stroke neurorepair agents, particularly those modulating neurotrophic signaling.